Canada-Approved Medicine
This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canadas Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
REMSContraindicated in:
Use Cautiously in:
CNS: dizziness, headache.
GI: dyspepsia, flatulence, gastritis, abdominal distension, abdominal pain, ↓ appetite, cholestasis, constipation, diarrhea, nausea.
GU: erectile dysfunction, renal failure.
Derm: alopecia, pruritus, urticaria, photosensitivity reaction, alopecia, rash.
MS: RHABDOMYOLYSIS, muscle cramps, muscular weakness, myalgia.
Misc: hypersensitivity reactions including anaphylaxis.
Drug-Drug:
Therapeutic Classification: lipid-lowering agents
Pharmacologic Classification: fibric acid derivatives
Absorption: Well absorbed (100%) following oral admininistration.
Distribution: Unknown.
Metabolism/Excretion: 50% metabolized, 50% excreted unchanged in urine, remainder as metabolites. 3% excreted in feces.
Half-life: 12 hr.